Stifel analyst Tom Stephan has maintained a Hold rating on TransMedics Group (NASDAQ: TMDX) and raised the price target to $80 from $75. The adjustment reflects a revised valuation outlook for the company.

The revised price target of $80 represents an increase from the previous target of $75. TransMedics Group continues to trade on the NASDAQ under the ticker symbol TMDX.

Johnson Fistel, PLLP is investigating TransMedics Group, Inc. on behalf of investors who suffered losses following recent disclosures concerning margin pressure and investments. The law firm is examining whether TransMedics complied with federal securities laws after the company reported its first quarter 2026 financial results on May 5, 2026. TransMedics' stock price declined sharply after the company revealed that adjusted operating margin for 2026 was expected to be below 2025 levels despite continued revenue growth expectations.

TransMedics reported total revenue of approximately $173.9 million for the first quarter of 2026, representing a 21% increase compared to the first quarter of 2025. However, profitability metrics contracted significantly. Gross margin decreased to 58% from 61% in the prior-year period. Operating margin fell to 7.6% from 19.1% in the first quarter of 2025, while adjusted operating margin dropped to 10.4% from 20.7% in the same period last year.

The company attributed the margin compression primarily to investments to support growth and scale, alongside higher supply chain and operating costs compared to the prior year. Operating expenses increased to approximately $87.9 million, up from $60.8 million in the first quarter of 2025. This rise was driven by increased research and development investment and broader organizational investments to support growth.

Financial Performance Overview

The following table details the financial performance of TransMedics for the first quarter of 2026 compared to the prior year:

During the earnings call on May 5, 2026, management discussed continued investments in clinical programs, technology, international expansion initiatives, and the National OCS Program (NOP) aviation and logistics network. Despite the revenue growth, the company advised that adjusted operating margin for 2026 would likely remain below 2025 levels.

Johnson Fistel is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder litigation involving securities fraud and breaches of fiduciary duties. Investors who purchased TransMedics securities and suffered losses are encouraged to contact the firm to discuss their rights.